{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:53:57Z","timestamp":1773683637999,"version":"3.50.1"},"reference-count":48,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["IDDT"],"published-print":{"date-parts":[[2019,12,23]]},"abstract":"<jats:sec><jats:title\/><jats:p>The introduction of more efficient antiviral drugs are common cause drug-induced acute kidney injury (AKI). The true prevalence of antiviral drugs induced nephrotoxicity is hardly determined. It causes AKI by many mechanisms including acute tubular necrosis (ATN), allergic interstitial nephritis (AIN), and crystal nephropathy. ATN has been described with a few kinds of antiviral drugs such as cidofovir, adefovir and tenofovir with unique effects on transporter defects, apoptosis, and mitochondrial injury. AIN from atazanavir is a rapid onset of AKI and usually nonoliguric but dialytic therapy are needed because of severity. Additionally, crystal nephropathy from acyclovir, indinavir, and foscarnet can cause AKI due to intratubular obstruction. In this article, the mechanisms of antiviral drug-induced AKI were reviewed and strategies for preventing AKI were mentioned.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1871526519666190617154137","type":"journal-article","created":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T09:45:33Z","timestamp":1561628733000},"page":"375-382","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Antiviral Drugs and Acute Kidney Injury (AKI)"],"prefix":"10.2174","volume":"19","author":[{"given":"Wattana","family":"Leowattana","sequence":"first","affiliation":[{"name":"Department of Clinical Tropical Medicine, Mahidol University, 420\/6 Rajavithi Road, Rachatawee, Bangkok 10400, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/S0140-6736(11)61454-2","volume":"380","author":"Bellomo R.","year":"2012","unstructured":"Bellomo R.; Kellum J.A.; Ronco C.; Acute kidney injury. Lancet 2012,380(9843),756-766","journal-title":"Lancet"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.pop.2014.08.005","volume":"41","author":"Eftekhari P.","year":"2014","unstructured":"Eftekhari P.; Evaluation of acute kidney injury in the hospital setting. Prim Care 2014,41(4),779-802","journal-title":"Prim Care"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/nep.12751","volume":"21","author":"Mesropian P.D.","year":"2016","unstructured":"Mesropian P.D.; Othersen J.; Mason D.; Wang J.; Asif A.; Mathew R.O.; Community-acquired acute kidney injury: A challenge and opportunity for primary care in kidney health. Nephrology (Carlton) 2016,21(9),729-735","journal-title":"Nephrology (Carlton)"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.2215\/CJN.00710113","volume":"8","author":"Susantitaphong P.","year":"2013","unstructured":"Susantitaphong P.; Cruz D.N.; Cerda J.; Abulfaraj M.; Alqahtani F.; Koulouridis I.; Jaber B.L.; World incidence of AKI: a meta-analysis. Clin J Am Soc Nephrol 2013,8(9),1482-1493","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1001\/jama.294.7.813","volume":"294","author":"Uchino S.","year":"2005","unstructured":"Uchino S.; Kellum J.A.; Bellomo R.; Doig G.S.; Morimatsu H.; Morgera S.; Schetz M.; Tan I.; Bouman C.; Macedo E.; Gibney N.; Tolwani A.; Ronco C.; Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005,294(7),813-818","journal-title":"JAMA"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1053\/j.ajkd.2005.02.010","volume":"45","author":"Izzedine H.","year":"2005","unstructured":"Izzedine H.; Launay-Vacher V.; Deray G.; Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 2005,45(5),804-817","journal-title":"Am J Kidney Dis"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.2215\/CJN.02050309","volume":"4","author":"Perazella M.A.","year":"2009","unstructured":"Perazella M.A.; Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol 2009,4(7),1275-1283","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1146\/annurev.pharmtox.44.101802.121856","volume":"44","author":"Lee W.","year":"2004","unstructured":"Lee W.; Kim R.B.; Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol 2004,44,137-166","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1128\/AAC.49.3.1010-1016.2005","volume":"49","author":"Naesens L.","year":"2005","unstructured":"Naesens L.; Lenaerts L.; Andrei G.; Snoeck R.; Van Beers D.; Holy A.; Balzarini J.; De Clercq E.; Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob Agents Chemother 2005,49(3),1010-1016","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1111\/j.1600-6143.2008.02269.x","volume":"8","author":"Bernhoff E.","year":"2008","unstructured":"Bernhoff E.; Gutteberg T.J.; Sandvik K.; Hirsch H.H.; Rinaldo C.H.; Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression. Am J Transplant 2008,8(7),1413-1422","journal-title":"Am J Transplant"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1128\/AAC.39.6.1247","volume":"39","author":"Cundy K.C.","year":"1995","unstructured":"Cundy K.C.; Petty B.G.; Flaherty J.; Fisher P.E.; Polis M.A.; Wachsman M.; Lietman P.S.; Lalezari J.P.; Hitchcock M.J.; Jaffe H.S.; Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1995,39(6),1247-1252","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2165\/00003088-199936020-00004","volume":"36","author":"Cundy K.C.","year":"1999","unstructured":"Cundy K.C.; Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet 1999,36(2),127-143","journal-title":"Clin Pharmacokinet"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/00042560-199804010-00008","volume":"17","author":"Lalezari J.P.","year":"1998","unstructured":"Lalezari J.P.; Holland G.N.; Kramer F.; McKinley G.F.; Kemper C.A.; Ives D.V.; Nelson R.; Hardy W.D.; Kuppermann B.D.; Northfelt D.W.; Youle M.; Johnson M.; Lewis R.A.; Weinberg D.V.; Simon G.L.; Wolitz R.A.; Ruby A.E.; Stagg R.J.; Jaffe H.S.; Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1998,17(4),339-344","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/135965350501000110","volume":"10","author":"Ortiz A.","year":"2005","unstructured":"Ortiz A.; Justo P.; Sanz A.; Melero R.; Caramelo C.; Guerrero M.F.; Strutz F.; M\u00fcller G.; Barat A.; Egido J.; Tubular cell apoptosis and cidofovir-induced acute renal failure. Antivir Ther (Lond) 2005,10(1),185-190","journal-title":"Antivir Ther (Lond)"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1093\/ndt\/17.1.148","volume":"17","author":"Meier P.","year":"2002","unstructured":"Meier P.; Dautheville-Guibal S.; Ronco P.M.; Rossert J.; Cidofovir-induced end-stage renal failure. Nephrol Dial Transplant 2002,17(1),148-149","journal-title":"Nephrol Dial Transplant"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1681\/ASN.V113383","volume":"11","author":"Ho E.S.","year":"2000","unstructured":"Ho E.S.; Lin D.C.; Mendel D.B.; Cihlar T.; Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol 2000,11(3),383-393","journal-title":"J Am Soc Nephrol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1517\/14656566.2012.649727","volume":"13","author":"Segovia M.C.","year":"2012","unstructured":"Segovia M.C.; Chacra W.; Gordon S.C.; Adefovir dipivoxil in chronic hepatitis B: history and current uses. Expert Opin Pharmacother 2012,13(2),245-254","journal-title":"Expert Opin Pharmacother"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/apt.14497","volume":"47","author":"Wong G.L.","year":"2018","unstructured":"Wong G.L.; Seto W.K.; Wong V.W.; Yuen M.F.; Chan H.L.; Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B. Aliment Pharmacol Ther 2018,47(6),730-737","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1124\/mol.56.3.570","volume":"56","author":"Cihlar T.","year":"1999","unstructured":"Cihlar T.; Lin D.C.; Pritchard J.B.; Fuller M.D.; Mendel D.B.; Sweet D.H.; The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol 1999,56(3),570-580","journal-title":"Mol Pharmacol"},{"key":"ref=20","first-page":"844","volume":"294","author":"Wada S.","year":"2000","unstructured":"Wada S.; Tsuda M.; Sekine T.; Cha S.H.; Kimura M.; Kanai Y.; Endou H.; Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs. J Pharmacol Exp Ther 2000,294(3),844-849","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1053\/hupa.2001.25586","volume":"32","author":"Tanji N.","year":"2001","unstructured":"Tanji N.; Tanji K.; Kambham N.; Markowitz G.S.; Bell A.; D\u2019agati V.D.; Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol 2001,32(7),734-740","journal-title":"Hum Pathol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1056\/NEJMoa042957","volume":"352","author":"Hadziyannis S.J.","year":"2005","unstructured":"Hadziyannis S.J.; Tassopoulos N.C.; Heathcote E.J.; Chang T.T.; Kitis G.; Rizzetto M.; Marcellin P.; Lim S.G.; Goodman Z.; Ma J.; Arterburn S.; Xiong S.; Currie G.; Brosgart C.L.; Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med Adefovir Dipivoxil 438 Study Group2005,352(26),2673-2681","journal-title":"N Engl J Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","volume":"381","author":"Marcellin P.","year":"2013","unstructured":"Marcellin P.; Gane E.; Buti M.; Afdhal N.; Sievert W.; Jacobson I.M.; Washington M.K.; Germanidis G.; Flaherty J.F.; Aguilar Schall R.; Bornstein J.D.; Kitrinos K.M.; Subramanian G.M.; McHutchison J.G.; Heathcote E.J.; Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013,381(9865),468-475","journal-title":"Lancet"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2165\/00003088-200443090-00003","volume":"43","author":"Kearney B.P.","year":"2004","unstructured":"Kearney B.P.; Flaherty J.F.; Shah J.; Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004,43(9),595-612","journal-title":"Clin Pharmacokinet"},{"key":"ref=25","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/354908","volume":"2011","author":"Fernandez-Fernandez B.","year":"2011","unstructured":"Fernandez-Fernandez B.; Montoya-Ferrer A.; Sanz A.B.; Sanchez-Ni\u00f1o M.D.; Izquierdo M.C.; Poveda J.; Sainz-Prestel V.; Ortiz-Martin N.; Parra-Rodriguez A.; Selgas R.; Ruiz-Ortega M.; Egido J.; Ortiz A.; Tenofovir nephrotoxicity: 2011 update. Aids Res Treat 2011,2011","journal-title":"Aids Res Treat"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/hep.27894","volume":"62","author":"Wong G.L.","year":"2015","unstructured":"Wong G.L.; Tse Y.K.; Wong V.W.; Yip T.C.; Tsoi K.K.; Chan H.L.; Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects. Hepatology 2015,62(3),684-693","journal-title":"Hepatology"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/apt.13440","volume":"43","author":"Ahn J.","year":"2016","unstructured":"Ahn J.; Lee H.M.; Lim J.K.; Pan C.Q.; Nguyen M.H.; Ray Kim W.; Mannalithara A.; Trinh H.; Chu D.; Tran T.; Min A.; Do S.; Te H.; Reddy K.R.; Lok A.S.; Entecavir safety and effectiveness in a national cohort of treatment-na\u00efve chronic hepatitis B patients in the US - the ENUMERATE study. Aliment Pharmacol Ther 2016,43(1),134-144","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1007\/s10620-017-4448-7","volume":"62","author":"Riveiro-Barciela M.","year":"2017","unstructured":"Riveiro-Barciela M.; Tabernero D.; Calleja J.L.; Lens S.; Manzano M.L.; Rodr\u00edguez F.G.; Crespo J.; Piqueras B.; Pascasio J.M.; Comas C.; Gutierrez M.L.; Aguirre A.; Su\u00e1rez E.; Garc\u00eda-Samaniego J.; Rivero M.; Acero D.; Fernandez-Bermejo M.; Moreno D.; S\u00e1nchez-Pobre P.; de Cuenca B.; Moreno-Palomares J.J.; Esteban R.; Buti M.; Effectiveness andsafety of entecavir or tenofovir in a Spanish cohort of chronic hepatitisB patients: validation of the page-B score to predict hepatocellular carcinoma. Dig Dis Sci 2017,62(3),784-793","journal-title":"Dig Dis Sci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.5414\/CN10838","volume":"82","author":"Raghavan R.","year":"2014","unstructured":"Raghavan R.; Eknoyan G.; Acute interstitial nephritis - a reappraisal and update. Clin Nephrol 2014,82(3),149-162","journal-title":"Clin Nephrol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/ki.2010.89","volume":"77","author":"Praga M.","year":"2010","unstructured":"Praga M.; Gonz\u00e1lez E.; Acute interstitial nephritis. Kidney Int 2010,77(11),956-961","journal-title":"Kidney Int"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2165\/00003495-200969080-00009","volume":"69","author":"Croom K.F.","year":"2009","unstructured":"Croom K.F.; Dhillon S.; Keam S.J.; Atazanavir: a review of its use in the management of HIV-1 infection. Drugs 2009,69(8),1107-1140","journal-title":"Drugs"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1016\/S0272-6386(04)01093-5","volume":"44","author":"Brewster U.C.","year":"2004","unstructured":"Brewster U.C.; Perazella M.A.; Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am J Kidney Dis 2004,44(5),e81-e84","journal-title":"Am J Kidney Dis"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00428-007-0418-3","volume":"450","author":"Schmid S.","year":"2007","unstructured":"Schmid S.; Opravil M.; Moddel M.; Huber M.; Pfammatter R.; Keusch G.; Ambuhl P.; Wuthrich R.P.; Moch H.; Varga Z.; Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies. Virchows Arch 2007,450(6),665-670","journal-title":"Virchows Arch"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/ckj\/sfv015","volume":"8","author":"Hara M.","year":"2015","unstructured":"Hara M.; Suganuma A.; Yanagisawa N.; Imamura A.; Hishima T.; Ando M.; Atazanavir nephrotoxicity. Clin Kidney J 2015,8(2),137-142","journal-title":"Clin Kidney J"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrneph.2017.10","volume":"13","author":"Mulay S.R.","year":"2017","unstructured":"Mulay S.R.; Anders H.J.; Crystal nephropathies: mechanisms of crystal-induced kidney injury. Nat Rev Nephrol 2017,13(4),226-240","journal-title":"Nat Rev Nephrol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1517\/14740338.7.2.147","volume":"7","author":"Yarlagadda S.G.","year":"2008","unstructured":"Yarlagadda S.G.; Perazella M.A.; Drug-induced crystal nephropathy: an update. Expert Opin Drug Saf 2008,7(2),147-158","journal-title":"Expert Opin Drug Saf"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2165\/00003495-199447010-00009","volume":"47","author":"Wagstaff A.J.","year":"1994","unstructured":"Wagstaff A.J.; Faulds D.; Goa K.L.; Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994,47(1),153-205","journal-title":"Drugs"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/0002-9343(88)90313-0","volume":"84","author":"Sawyer M.H.","year":"1988","unstructured":"Sawyer M.H.; Webb D.E.; Balow J.E.; Straus S.E.; Acyclovir-induced renal failure. Clinical course and histology. Am J Med 1988,84(6),1067-1071","journal-title":"Am J Med"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1093\/infdis\/151.2.362","volume":"151","author":"Bean B.","year":"1985","unstructured":"Bean B.; Aeppli D.; Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster. J Infect Dis 1985,151(2),362-365","journal-title":"J Infect Dis"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0002-9343(99)00041-8","volume":"106","author":"Perazella M.A.","year":"1999","unstructured":"Perazella M.A.; Crystal-induced acute renal failure. Am J Med 1999,106(4),459-465","journal-title":"Am J Med"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.2165\/00003495-199958060-00011","volume":"58","author":"Plosker G.L.","year":"1999","unstructured":"Plosker G.L.; Noble S.; Indinavir: a review of its use in the management of HIV infection. Drugs 1999,58(6),1165-1203","journal-title":"Drugs"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrneph.2009.142","volume":"5","author":"Izzedine H.","year":"2009","unstructured":"Izzedine H.; Harris M.; Perazella M.A.; The nephrotoxic effects of HAART. Nat Rev Nephrol 2009,5(10),563-573","journal-title":"Nat Rev Nephrol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2174\/157488607780598269","volume":"2","author":"Rho M.","year":"2007","unstructured":"Rho M.; Perazella M.A.; Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients. Curr Drug Saf 2007,2(2),147-154","journal-title":"Curr Drug Saf"},{"key":"ref=44","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2001.27732","volume":"38","author":"Reilly R.F.","year":"2001","unstructured":"Reilly R.F.; Tray K.; Perazella M.A.; Indinavir nephropathy revisited: a pattern of insidious renal failure with identifiable risk factors. Am J Kidney Dis 2001,38(4)","journal-title":"Am J Kidney Dis"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"8S","DOI":"10.1016\/0002-9343(92)90330-E","volume":"92","author":"Lietman P.S.","year":"1992","unstructured":"Lietman P.S.; Clinical pharmacology: foscarnet. Am J Med 1992,92(2A),8S-11S","journal-title":"Am J Med"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/ajkd.1998.v32.pm9740154","volume":"32","author":"Maurice-Estepa L.","year":"1998","unstructured":"Maurice-Estepa L.; Daudon M.; Katlama C.; Jouanneau C.; Sazdovitch V.; Lacour B.; Beaufils H.; Identification of crystals in kidneys of AIDS patients treated with foscarnet. Am J Kidney Dis 1998,32(3),392-400","journal-title":"Am J Kidney Dis"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1097\/00002030-199307000-00006","volume":"7","author":"Seidel E.A.","year":"1993","unstructured":"Seidel E.A.; Koenig S.; Polis M.A.; A dose escalation study to determine the toxicity and maximally tolerated dose of foscarnet. AIDS 1993,7(7),941-945","journal-title":"AIDS"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"5763","DOI":"10.1016\/j.bmcl.2004.09.064","volume":"14","author":"Rusconi S.","year":"2004","unstructured":"Rusconi S.; Innocenti A.; Vullo D.; Mastrolorenzo A.; Scozzafava A.; Supuran C.T.; Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with phosphates, carbamoyl phosphate, and the phosphonate antiviral drug foscarnet. Bioorg Med Chem Lett 2004,14(23),5763-5767","journal-title":"Bioorg Med Chem Lett"}],"container-title":["Infectious Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/172630","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T02:55:11Z","timestamp":1663815311000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/172630\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,23]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,12,23]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871526519666190617154137","relation":{},"ISSN":["1871-5265"],"issn-type":[{"value":"1871-5265","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,23]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-09-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}